BECKY BOLE: Open Payments
NPI 1043621576 · NAMPA, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$487 in 22 payments from 12 companies in 2025. Trend: 2023 $1,836 · 2024 $1,000 · 2025 $487
Food & beverage: $487
| Company | Payments | Amount |
|---|---|---|
| Antares Pharma, Inc. | 4 | $96 |
| Otsuka America Pharmaceutical, Inc. | 5 | $90 |
| E.R. Squibb & Sons, L.L.C. | 1 | $77 |
| Alkermes, Inc. | 3 | $64 |
| Novo Nordisk Inc | 1 | $26 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $22 |
| Corium, LLC | 2 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| Corcept Therapeutics | 1 | $19 |
Products named: XYOSTED, COBENFY, REXULTI, LYBALVI, ABILIFY ASIMTUFII, ARISTADA, Wegovy, CAPLYTA.
Industry payments across ID — which companies pay providers there.
